secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2024-04-29T23:59:59+00:00
Accession:  0001193125-24-122215
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Stoke Therapeutics names Thomas Leggett CFO; Stephen Tulipano resigns
---------------------------------------------------------------------

- Thomas Leggett appointed CFO effective May 7, 2024; previously CFO at Affinia Therapeutics and Black Diamond Therapeutics.
- Leggett receives $475,000 base salary, 40% bonus target, and option for 396,200 shares vesting over 4 years.
- Current CFO Stephen Tulipano resigns effective May 7; will serve as advisor through Dec 31, 2024.
- Tulipano retains equity vesting during transition period and up to $15,000 in outplacement services.
- Leggett holds B.A. from Columbia and M.B.A. from Wharton; also board member at Clover Biopharmaceuticals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000119312524122215/0001193125-24-122215-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000119312524122215/d810575d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-122215

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer